AIM ImmunoTech Inc. AIM AMEX

American Stock Excha • Healthcare • Biotechnology • US • USD

SharesGrow Score

28/100

1/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

AIM ImmunoTech Inc. (AIM) has a negative trailing P/E of -0.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -842.71%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -0.1); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -842.71%).
Trailing Earnings Yield -842.71% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.

Overall SharesGrow Score: 27/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

28/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✓

FUTURE

100/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

15/100

→ Income

GROWTH

40/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — AIM

Valuation Multiples

P/E (TTM)-0.1

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio-0.17

P/S Ratio20.85

EV/EBITDA-0.5

Per Share Data

EPS (TTM)$-4.54

Book Value / Share$-3.18

Revenue / Share$0.03

FCF / Share$-3.66

Yields & Fair Value

Earnings Yield-842.71%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-5.2	0.10	2.52	424.36	-
2017	-3.2	0.21	2.99	59.57	-
2018	-2.1	0.09	3.99	56.21	-
2019	-0.5	0.01	0.40	36.45	-
2020	-10.3	0.12	2.41	906.99	-
2021	-5.9	0.55	1.99	836.75	-
2022	-2.0	-11.47	1.00	274.05	-
2023	-1.9	-0.04	5.42	274.53	-
2024	-1.7	0.03	-21.99	170.97	-
2025	-0.1	0.01	-0.19	20.78	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-15.13	$92K	$-7.5M	-8154.3%
2017	$-12.67	$437K	$-8.26M	-1889.9%
2018	$-9.77	$367K	$-9.81M	-2673.8%
2019	$-2.97	$140K	$-10.83M	-7732.9%
2020	$-0.51	$163K	$-16.26M	-9974.2%
2021	$-0.45	$135K	$-21.51M	-15935.6%
2022	$-0.44	$141K	$-21.09M	-14954.6%
2023	$-0.60	$202K	$-28.96M	-14337.6%
2024	$-0.31	$170K	$-17.32M	-10188.2%
2025	$-8.62	$88K	$-13.96M	-15861.4%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-4.33	$-4.33 – $-4.33	$100K	$100K – $100K	1
2027	$-1.61	$-1.61 – $-1.61	$9.75M	$9.75M – $9.75M	1
2028	$-1.46	$-1.46 – $-1.46	$51.04M	$51.04M – $51.04M	1
2029	$-1.51	$-1.51 – $-1.51	$74.45K	$74.45K – $74.45K	1